| 杨朝霞,袁小燕,李为.131I治疗甲状腺乳头状癌临床疗效及对甲状腺相关抗体和基质金属蛋白酶水平的影响.[J].中南医学科学杂志.,2021,(3):340-343. |
| 131I治疗甲状腺乳头状癌临床疗效及对甲状腺相关抗体和基质金属蛋白酶水平的影响 |
| Clinical efficacy of 131I in the treatment of papillary thyroid carcinoma and its influence on thyroid associated antibodies and matrix metalloproteinases |
| 投稿时间：2020-12-17 修订日期：2021-02-03 |
| DOI：10.15972/j.cnki.43-1509/r.2021.03.020 |
| 中文关键词: 碘131 甲状腺乳头状癌 甲状腺相关抗体 基质金属蛋白酶 甲状腺过氧化物酶抗体 抗甲状腺球蛋白抗体 |
| 英文关键词:131I differentiated thyroid carcinoma thyroid associated antibody matrix metalloproteinase thyroid peroxidase antibody antithyroid globulin antibody |
| 基金项目: |
|
| 摘要点击次数: 495 |
| 全文下载次数: 377 |
| 中文摘要: |
| 目的分析碘131(131I)治疗甲状腺乳头状癌的临床疗效,及131I治疗对甲状腺相关抗体和基质金属蛋白酶水平的影响。 方法选择90例甲状腺乳头状癌(PCT)患者,均一次性口服131I治疗,分析131I对PCT的临床治疗效果。采用全自动生化分析仪分析治疗前后血细胞和肝肾功能指标的变化；放射免疫法分析血清甲状腺相关抗体变化；酶联免疫吸附测定法分析血清基质金属蛋白酶水平的变化。 结果90例甲状腺乳头状癌患者经131I治疗总有效率为86.66%。与131I治疗前比较,131I治疗后患者血清中甲状腺过氧化物酶抗体(TPO-Ab)、抗甲状腺球蛋白抗体(anti-TGAb)、基质金属蛋白酶2/9(MMP2/9)及基质金属蛋白酶抑制剂1/2(TIMP1/2)水平均明显降低(P＜0.05),而白细胞、血小板、淋巴细胞、红细胞、血尿素氮(BUN)、谷丙转氨酶(ALT)、谷草转氨酶(AST)及碱性磷酸酶(ALP)水平无明显变化(P＞0.05)。 结论131I治疗甲状腺乳头状癌患者有较好临床疗效,且明显降低患者血清甲状腺相关抗体及基质金属蛋白酶水平,且不影响肝肾功能,安全性高。 |
| 英文摘要: |
| To analyze the clinical effect of iodine131 (131I) in the treatment of thyroid papillary carcinoma and the effect of 131I on the level of thyroid related antibodies and matrix metalloproteinase. Methods90 cases of papillary thyroid carcinoma (PCT) were treated with 131I once, and the clinical effect of 131I on PCT was analyzed. The changes of blood cells and liver and kidney function indexes before and after treatment were analyzed by automatic biochemical analyzer; the changes of serum thyroid related antibodies were analyzed by radioimmunoassay; the changes of serum matrix metalloproteinase were analyzed by enzyme-linked immunosorbent assay. ResultsThe total effective rate of 131I treatment was 86.66% in 90 patients with papillary thyroid cancer. Compared with the pre-131i treatment, the levels of TPO AB, anti thyroglobulin, MMP2/9, TIMP1/2 were significantly reduced (P＜0.05), while the levels of RBC, bun, GPT were significantly decreased (P＜0.05). There was no significant change in WBC, platelet, lymphocyte, ALT, AST and ALP (P＞0.05). Conclusion131I has a good clinical effect on papillary thyroid cancer, significantly reduces the level of thyroid related antibodies and matrix metalloproteinases in the serum of patients, does not affect the function of liver and kidney, and is safe. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|